Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ProQR Therapeutics
Biotech
ProQR, Théa ink new pact for eye assets after old one collapsed
After an earlier version of the deal crumbled, ProQR has finally managed to sell off its ophthalmology assets to Laboratoires Théa.
Gabrielle Masson
Dec 8, 2023 11:01am
Thea drops ProQR eye asset purchase after staff refuse to move
Sep 27, 2023 12:38pm
ProQR offloads 2 eye disease assets to Théa for $14M upfront
Aug 1, 2023 10:10am
Lilly doubles down on ProQR's RNA tech in $75M deal expansion
Dec 22, 2022 10:38am
After a year of 'right sizing,' will biotech rebloom in 2023?
Dec 22, 2022 5:00am
Biotechs cut pipeline prospects to focus on priority programs
Aug 11, 2022 9:43am
